1. Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). (April 2017) Authors: Savona, M.R.; Garcia-Manero, G.; Roboz, G.J.; Walsh, K.J.; Kropf, P.L.; Issa, J.P.; O'Connell, C.L.; Tibes, R.; Yee, K.W.L.; Stock, W.; Lunin, S.; Berdeja, J.G.; Naim, S.; Hao, Y.; Azab, M.; Kantarjian, H. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. (June 2017) Authors: Zinzani, P.; Wagner‐Johnston, N.; Miller, C.; Ardeshna, K.; Tertreault, S.; Assouline, S.; Mayer, J.; Passamonti, F.; Lunin, S.; Pettitt, A.; Nagy, Z.; Tournilhac, O.; Abou‐Nassar, K.; Crump, M.; Jacobsen, E.; De Vos, S.; Youssoufian, H.; Porter, J.; Prado, S.; Flinn, I. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗